Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
Bluejay partners with SDVOSB distributor Lovell to build federal market access infrastructure ahead of potential FDA-cleared commercialization of its Symphony platform.
Rhea-AI Summary
Bluejay Diagnostics (BJDX) signed a distribution, co-marketing and strategic partnership with Lovell Government Services to prepare access to U.S. federal healthcare markets, effective for products that receive applicable FDA clearance or other required regulatory authorization.
Lovell will be Bluejay’s exclusive distributor for federal procurement opportunities that require or favor Service-Disabled Veteran-Owned Small Business set-aside or preferred status, including the VA, DoD, Military Health Systems and Indian Health Service, and will have non-exclusive rights for other federal, state and local opportunities. The collaboration aims to leverage Lovell’s federal contract vehicles such as VA FSS, GSA MAS, DLA DAPA and ECAT, as well as its AMSUS relationships. The framework is part of Bluejay’s strategy to build commercialization capabilities in parallel with its SYMON clinical study program and ongoing FDA 510(k) plans for the Symphony IL-6 sepsis test.
Positive
- Exclusive SDVOSB distribution for VA, DoD, MHS and IHS set-aside or preferred federal opportunities
- Access to key federal contract vehicles including VA FSS, GSA MAS, DLA DAPA and ECAT through Lovell
- Non-exclusive rights for Lovell to pursue additional federal, state and local government procurement
- Federal market groundwork established while SYMON-II pivotal study is planned to support a 510(k) FDA submission
Negative
- Symphony platform remains investigational and cannot be marketed in the U.S. without FDA authorization
- Commercial benefits are contingent on successful completion of SYMON studies and subsequent FDA clearance or other required regulatory authorization
News Explained
Bluejay Diagnostics’ partnership with Lovell remains a pre-commercial market-access framework: Symphony is investigational and lacks U.S. regulatory clearance, so the announcement does not itself authorize marketing or establish current product sales.
Details
Market reaction after federal market partnership: BJDX +14.76%
Following this news, BJDX has gained 14.76%, reflecting a significant positive market reaction. Argus tracked a peak move of +16.3% during the session. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner has triggered 31 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.96. Trading volume is exceptionally heavy at 226.6x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- VHA proposed FY2026 budget
- $165.1 billion
- Veterans Health Administration
- DHA proposed FY2026 budget
- $64 billion
- Defense Health Agency
- IHS proposed FY2026 budget
- $8.1 billion
- Indian Health Service
- VHA medical centers
- 170 major medical centers
- Veterans Health Administration network
- VHA outpatient clinics
- 1,193 outpatient clinics
- Veterans Health Administration network
- DoD healthcare facilities
- 45 military hospitals
- Department of Defense healthcare system
- DoD medical clinics
- 572 military medical clinics
- Department of Defense healthcare system
- IHS population served
- 2.8 million American Indians and Alaska Natives
- Indian Health Service
Previous Partnership Reports
-
Partnership advanced U.S. manufacturing, distribution, and supply-chain infrastructure for Symphony.
-
Expanded partner role across manufacturing, regulatory support, supply chain, and market introduction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sdvosb regulatory
510(k) regulatory
investigational device regulatory
il-6 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels
ACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, and Lovell Government Services, Inc. (“Lovell”), a Service-Disabled Veteran-Owned Company (“SDVOSB”) specializing in federal healthcare distribution, today announced a distribution, co-marketing and strategic partnership designed to support the introduction of Bluejay’s products into the U.S. federal healthcare market following applicable U.S. Food and Drug Administration (“FDA”) clearance or other required regulatory authorization.
The partnership is designed to establish a scalable federal market access and procurement infrastructure in advance of potential commercialization, positioning Bluejay to efficiently pursue opportunities across some of the largest government-operated healthcare systems in the United States, subject to applicable FDA clearance or other required regulatory authorization for its products.
Under the agreement, Lovell will serve as Bluejay’s exclusive distributor for federal procurement opportunities requiring or favoring SDVOSB set-aside and preferred status, including opportunities within the U.S. Department of Veterans Affairs (“VA”), Department of Defense (“DoD”), Military Health Systems (“MHS”) and Indian Health Service (“IHS”). Lovell will also have non-exclusive rights to participate in open-market federal, state and local government procurement opportunities.
Strategic Access to a Large Federal Healthcare Market
The partnership provides Bluejay with a strategic framework to access and pursue opportunities across the significant U.S. federal healthcare market, creating a potential pathway for commercial expansion if and when its devices receive applicable FDA clearance or approval and are commercially launched in the United States.
The Veterans Health Administration (“VHA”), the largest integrated healthcare system in the United States, encompasses approximately 170 major medical centers and 1,193 outpatient clinics, with a proposed FY2026 budget of approximately
Together, these federal healthcare systems represent an extensive network of hospitals, medical centers, outpatient clinics and other care settings in which timely access to clinically relevant information may be important.
“We believe this partnership represents an important step in building Bluejay’s commercial infrastructure well ahead of potentially marketing medical devices in the US.” said Neil Dey, Chief Executive Officer of Bluejay Diagnostics. “The scale of the federal healthcare system is significant, and establishing a pathway into these markets could provide Bluejay with an important future commercialization channel.”
Dey continued, “We believe regulatory, manufacturing and commercial readiness should advance in parallel. Lovell brings established federal contracting infrastructure, SDVOSB capabilities and experience navigating government procurement pathways that would be difficult and time-consuming for Bluejay to develop independently.”
Lovell Brings Established Federal Market Infrastructure
Lovell Government Services specializes in helping medical and healthcare companies navigate the U.S. federal marketplace. Its experience includes working with VA medical centers, military hospitals and clinics, IHS facilities and other federal healthcare organizations.
Through the partnership, Lovell will leverage its SDVOSB status, federal contracting capabilities and industry relationships to support market development, facilitate appropriate introductions and pursue federal procurement opportunities for Bluejay. The parties may also collaborate on educational initiatives, conferences, customer engagement and other federal market-development activities.
Lovell’s established federal procurement infrastructure includes access to contract vehicles such as the VA Federal Supply Schedule (“FSS”), GSA Advantage, GSA Multiple Award Schedule (“MAS”), Defense Logistics Agency (“DLA”) DAPA and Electronic Catalog (“ECAT”). ECAT is a preferred DoD procurement vehicle for medical supplies and devices and is also utilized by the VA and IHS.
Lovell also participates in the Association of Military Surgeons of the United States (“AMSUS”), providing potential exposure to more than 8,000 federal health professionals through publications, meetings and conferences.
“We are proud to partner with Bluejay Diagnostics as they prepare to bring the Symphony platform to market. At Lovell, our mission is to connect innovative healthcare technologies with the federal healthcare providers serving our Veterans, active-duty service members, and their families. By establishing the necessary contracting and procurement pathways now, we can help position Bluejay to efficiently reach these critical healthcare systems following applicable FDA clearance,” said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.
Building Commercial Readiness in Parallel With Regulatory Development
The partnership reflects Bluejay’s broader strategy of building commercialization capabilities while advancing its clinical, regulatory and manufacturing programs. Bluejay and Lovell may jointly pursue federal market-development initiatives and engage appropriate healthcare, clinical, innovation and procurement stakeholders in preparation for potential future commercialization.
Note: The Company's Symphony™ rapid diagnostic platform is an investigational device and is limited by United States law to investigational use.
About the SYMON Clinical Study Program:
The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to the FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
About Lovell Government Services
Lovell Government Services has been a trusted Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor since 2013 with a proven track record of helping suppliers successfully navigate the federal marketplace. As a five-time Inc. 5000 honoree, Lovell partners with medical, dental, pharmaceutical, and healthcare technology companies to expand access to federal healthcare systems while helping agencies streamline procurement and improve patient care for Veterans, military personnel, and other federal beneficiaries.
Learn more at www.lovellgov.com.
Forward-Looking Statements:
This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, “Risk Factors” in its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026 and June 30, 2026. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
ir@bluejaydx.com
Website: www.bluejaydx.com
Lovell Government Services Contact:
Jeff McKay Lovell Government Services
media@lovellgov.com
850-912-4680
FAQ
What specific federal healthcare systems could Bluejay access through this partnership?
The framework targets opportunities within the Veterans Health Administration, Department of Defense healthcare system, Military Health Systems and Indian Health Service. These include approximately 170 VHA medical centers and 1,193 outpatient clinics, about 45 U.S. military hospitals and 572 military medical clinics, and around 170 IHS and tribally managed service units that together serve approximately 2.8 million American Indians and Alaska Natives.
What role will Lovell Government Services play in Bluejay’s federal market development?
Lovell will use its Service-Disabled Veteran-Owned Small Business status, federal contracting capabilities and relationships with VA medical centers, military hospitals, IHS facilities and other organizations to support market development. Activities may include pursuing procurement opportunities, facilitating introductions, collaborating on educational initiatives, conferences, customer engagement and other federal market-development efforts.
What is the current regulatory and clinical status of Bluejay’s Symphony platform and IL-6 sepsis test?
The Symphony rapid diagnostic platform is an investigational device limited by U.S. law to investigational use. The SYMON clinical program includes SYMON-I (a pilot study on IL-6 levels and outcomes such as 28-day and in-hospital mortality), SYMON-II (a pivotal study that Bluejay plans to use to support a 510(k) submission to the FDA) and SYMON-III (a pilot study evaluating IL-6 levels in patients with increasing infection severity and risk of sepsis).
What product is Bluejay initially developing for this federal market pathway?
Bluejay’s first product candidate is an IL-6 test for sepsis on the Symphony System. It is designed to deliver accurate, reliable IL-6 results in approximately 20 minutes from sample-to-result to aid earlier and better triage and treatment decisions in sepsis care, once regulatory authorization is obtained.